Pain News and Research

Latest Pain News and Research

Sex can affect frequency and severity of adverse effects of vaccination

Biological differences between the sexes could be a significant predictor of responses to vaccines, according to researchers at the Johns Hopkins Bloomberg School of Public Health. They examined published data from numerous adult and child vaccine trials and found that sex is a fundamental, but often overlooked predictor of vaccine response that could help predict the efficacy of combating infectious disease.

13 May 2010

Regeneron Pharmaceuticals provides update on REGN727, REGN475 antibody product candidates

Regeneron Pharmaceuticals, Inc. (REGN) provided an update on two antibody product candidates in its pipeline and scheduled its first Investor Day to be held in New York City on July 15, 2010. Both product candidates, REGN727 (SAR236553) and, REGN475 (SAR164877) are being developed with sanofi-aventis under a global, strategic collaboration to discover, develop, and commercialize fully human antibodies.

13 May 2010

ABMC reports 7.6% increase in first-quarter 2010 net sales

American Bio Medica Corporation announced today its financial results for the three months ended March 31, 2010.

13 May 2010

RBC Life Sciences first-quarter net sales increase 16% to $7.0M

RBC Life Sciences, Inc., a provider of proprietary nutritional supplements, wound care and pain management products, today reported company-wide net sales of $7.0 million for the first quarter ended March 31, 2010, compared to net sales of $6.0 million for the same period during 2009, an increase of 16%.

12 May 2010

NIH awards PLx Pharma multiple grants for development of GI safer NSAIDs

PLx Pharma, a pharmaceutical company developing safer formulations of proven non-steroidal anti-inflammatory drugs (NSAIDs), today announced that it has been awarded multiple grants from the National Institutes of Health (NIH) totaling approximately $2,000,000. This funding has been awarded to support further advancement of a range of products currently under development by PLx.

12 May 2010

Gap between Hispanic and white asthma sufferers widen in the use daily medications

The gap between the proportion of black and white Americans with asthma who took an inhaled or oral medicine daily to prevent attacks grew wider between 2003 and 2006, according to the latest News and Numbers from the Agency for Healthcare Research and Quality.

12 May 2010

Daily dose of iron reduces breath-holding spells in children by 90%: Studies

An estimated one in 20 kids suffer from breath-holding spells, which come when they are upset, in pain or surprised. In some cases, the children twitch and jerk around involuntarily, as if they are having a seizure. Their faces sometimes turn blue or pale and they often faint.

12 May 2010

Pacira Pharmaceuticals receives $11.25M credit facility from GE Capital, Healthcare Financial Services

GE Capital, Healthcare Financial Services today announced it has provided an $11.25 million credit facility to Pacira Pharmaceuticals, Inc. The financing provides working capital, and facilitates advances toward regulatory approval and preparation for commercialization of Pacira's EXPAREL™ program.

12 May 2010

Update on Nymox Pharmaceutical's Phase 3 program for NX-1207

Nymox Pharmaceutical Corporation provided an update today on the Company's Phase 3 program for NX-1207, Nymox's investigational drug for benign prostatic hyperplasia. The most recent Safety Monitoring Committee meeting of April 30, 2010 for the Phase 3 U.S. pivotal trials of NX-1207 indicated no significant safety concerns for the trials to date.

12 May 2010

Adult patients with sickle cell disease may develop cognitive problems: Study

Sickle cell disease may affect brain function in adults who have few or mild complications of the inherited blood disease, according to results of the first study to examine cognitive functioning in adults with sickle cell disease.

12 May 2010

Australian TGA approves Acetadote for treatment of paracetamol poisoning

Cumberland Pharmaceuticals Inc. and Phebra Pty Ltd. today announced that Acetadote® (acetylcysteine) Injection has been granted regulatory approval for marketing and sale in Australia. Acetadote, an injectable drug used to treat acetaminophen (paracetamol) overdose, was approved by the Therapeutic Goods Administration (TGA), the government agency responsible for regulating drugs and medical devices in Australia.

12 May 2010

Overtime workers at 60% higher risk of heart-related problems

Working overtime is bad for the heart according to results from a long-running study following more than 10,000 civil servants in London (UK): the Whitehall II study.

11 May 2010

Abbott licenses 24 pharmaceutical products from Zydus Cadila

Further strengthening its global competitive position, Abbott today announced a licensing and supply agreement with Zydus Cadila of India for a portfolio of pharmaceutical products that Abbott will commercialize in 15 emerging markets, enabling the company to further accelerate its emerging markets growth.

11 May 2010

Advanced radiation techniques treat head and neck cancer, reduce swallowing complications

Researchers at the University of Michigan Comprehensive Cancer Center have applied advanced radiation techniques for head and neck cancer to avoid treating critical structures that affect swallowing and eating.

11 May 2010

Challenges faced in cardiac imaging

When patients present with chest pain or other high-risk symptoms of heart problems, doctors increasingly rely on nuclear imaging and computed tomography (CT) tests to find out whether there is evidence of heart disease, blockages in the coronary arteries or reduced blood flow to the heart. Results of these procedures can help guide life-saving prevention and treatment options.

11 May 2010

Progenics Pharmaceuticals reports net loss of $18.6M in first-quarter 2010

Progenics Pharmaceuticals, Inc. today announced its results of operations for the quarter ended March 31, 2010.

11 May 2010

Sucampo presents phase 3 trial results of lubiprostone in non-cancer pain patients with OBD at DDW 2010

Sucampo Pharmaceuticals, Inc. today announced the presentation of results from a phase 3 clinical trial investigating the use of lubiprostone in non-cancer pain patients with Opioid-induced Bowel Dysfunction (OBD). These results were the subject of an oral presentation at the Digestive Disease Week (DDW) 2010 conference in New Orleans, Louisiana, on May 5, 2010.

11 May 2010

Multicomponent psychological intervention helps reduce alexithymia and cancer pain

An Italian study published in the current issue of Psychotherapy and Psychosomatics examines the relationship between cancer pain and inability to express feelings and the effects of treatment.

10 May 2010

Study results of CTT's Calmare Pain Therapy for CIPN to be presented

Competitive Technologies, Inc. announced today that Thomas J. Smith, M.D., Endowed Chair of Palliative Care Research and Medical Director of the Thomas Palliative Care Unit Virginia Commonwealth University's Massey Cancer Center, will present results of his study evaluating the treatment of patients suffering from pain associated with chemotherapy-induced peripheral neuropathy (CIPN) using CTT's Calmare® Pain Therapy Treatment.

10 May 2010

QRxPharma reports successful outcome of Phase 1 trial for MoxDuo CR for chronic pain

QRxPharma announced today the successful outcome of a Phase 1 trial for MoxDuo CR, a controlled-release (CR) Dual-Opioid(TM) designed to provide 12 hours of pain relief in patients suffering from moderate to severe chronic pain (including cancer, lower back, osteoarthritis and neuropathic). The purpose of the trial was to determine which of the various experimental formulations provided the optimum duration of drug levels in the blood.

10 May 2010